<!DOCTYPE html>
<html lang=en>
<head>
<!--html_head_content-->
<meta charset=UTF-8>
<meta name="DESCRIPTION" content="Research Grants, Publications, Scientific Experts, Species, Research Topics, Genomes and Genes about plague vaccine">
<meta name="KEYWORDS" content="">
<meta name="robots" content="index, follow, noarchive">
<meta name="author" content="labome.org">
<link rel="canonical" href="/topics/chemicals/complex/biological/vaccines/bacterial/plague-vaccine-15630.html" />
<title>plague vaccine</title>

<!-- style sheets-->
<link href="http://aws.labome.org/css/main.css" rel="stylesheet" type="text/css" />
<!-- auto-complete -->
<script src="http://aws.labome.org/js/j3.js" type="text/javascript"></script>
<script src="http://aws.labome.org/js/j1.js" type="text/javascript"></script>

</head>
<body onload=document.f.q.focus()>
  
  <div id="outerdiv">
    <!-- outer div-->
    <div id="header">
      <!--  // header div // -->
      <div id="header_top"> </div>
      <div id="header_mid">
	<div id="header_logo"><!-- main logo--><a href="/"><img src="http://aws.labome.org/img/head_logo.gif" alt="Labome.Org" height="65" width="506"></a>
          </div>
	  <div id="header_subnav_search"><!-- header sub nav main search-->
	    <div style="float: right;">
	      <div id="header_subnav">
		<a href="/bin/l.pl?cmd=alertme&id=tp15630">alertme</a>	
	      </div>
	    </div>
	      <div style="clear:both;"></div>
	    <div style="float: left;">
	      <div id="mainsearch"><form action="/bin/l.pl" method="get" name="f" id="search">
		  <input id="header_searchbox" title="enter search text" name="q" maxlength="255" value="" type="text" /> &nbsp;
		  <input name="btnG" src="http://aws.labome.org/img/search.gif" alt="search Labome" id="header_goimg" type="image" /> 
		</form>
	      </div>
	  </div>
	  	      <div style="clear:both;"></div>
  
	</div> 
      </div>
      </div>
      <div id="nav_bar">
	You are here: Research Topics &gt; chemicals and drugs &gt; .. &gt; <a href="/topics/chemicals/complex/biological/vaccines-15616.html">vaccines</a> &gt; <a href="/topics/chemicals/complex/biological/vaccines/bacterial-vaccines-15618.html">bacterial vaccines</a> &gt; plague vaccine
      </div>
	<div id="ad"><a href="/bin/l.pl?link=www.labome.com/" onClick="pageTracker._trackEvent('ea', 'click');"><img src="http://aws.labome.org/ad/ad.gif" height="90" width="960" /></a></div>

	<div style="padding: 10px 0 0 0;"></div>	
	<div id="social" style="text-align:right; margin:3px;"> <div id="social_g" style="float: right;padding: 0 50px 0 0;"><script type="text/javascript" src="https://apis.google.com/js/plusone.js"></script><g:plusone size="medium" count="false"> </g:plusone></div><div id="social_f" style="float: right; width:48px;overflow:hidden;padding: 0 47px 0 0;"><div id="fb-root"></div><script>(function(d, s, id) {  var js, fjs = d.getElementsByTagName(s)[0];  if (d.getElementById(id)) return;  js = d.createElement(s); js.id = id;  js.src = "//connect.facebook.net/en_US/all.js#xfbml=1";  fjs.parentNode.insertBefore(js, fjs);}(document, 'script', 'facebook-jssdk'));</script><div class="fb-like" data-href="http://www.labome.org//topics/chemicals/complex/biological/vaccines/bacterial/plague-vaccine-15630.html" data-send="false" data-layout="button_count" data-width="48" data-show-faces="false"></div></div></div><div style="clear: both; height: 1px;overflow: hidden;"></div>
	<div id="content">
      <!-- content div-->
      <table id="home_content_tbl">
	<tr>
	  <td><div id="left_td"><div class="left_box"><h2 class="left_box_header">Research Topics</h2><div class="left_box_content"><ul><li><a href="/topics/diseases/bacterial/bacterial/gram/enterobacteriaceae/yersinia/plague-4820.html">plague</a><li><a href="/topics/organisms/bacteria/gram/gram/enterobacteriaceae/yersinia/yersinia-pestis-2699.html">yersinia pestis</a><li><a href="/topics/chemicals/biological/antigens/bacterial-antigens-15740.html">bacterial antigens</a><li><a href="/topics/chemicals/and/proteins/blood/immunoproteins/immunoglobulins/antibodies/bacterial-antibodies-15695.html">bacterial antibodies</a><li><a href="/topics/chemicals/biological/antigens/synthetic-vaccines-14984.html">synthetic vaccines</a><li><a href="/topics/chemicals/complex/biological/vaccines/subunit-vaccines-15655.html">subunit vaccines</a><li><a href="/topics/organisms/animals/animal/inbred/inbred/inbred-balb-c-mice-1405.html">inbred balb c mice</a><li><a href="/topics/chemicals/and/proteins/blood/immunoproteins/immunoglobulins/antibodies/immunoglobulin/immunoglobulin-g-14166.html">immunoglobulin g</a><li><a href="/topics/chemicals/complex/biological/vaccines/attenuated-vaccines-15648.html">attenuated vaccines</a><li><a href="/topics/chemicals/and/proteins/bacterial-proteins-14047.html">bacterial proteins</a><li><a href="/topics/organisms/animals/chordata/vertebrates/mammals/rodentia/muridae/murinae/mice-1728.html">mice</a><li><a href="/topics/diagnostic/investigative/immunologic/immunization/vaccination-16632.html">vaccination</a><li><a href="/topics/chemicals/and/proteins/recombinant/recombinant-fusion-proteins-14982.html">recombinant fusion proteins</a><li><a href="/topics/diagnostic/investigative/immunologic/immunization-16625.html">immunization</a><li><a href="/topics/physical/natural/biological/and/biological/microbiologic/virulence-19394.html">virulence</a><li><a href="/topics/organisms/animals/chordata/vertebrates/mammals/primates/haplorhini/catarrhini/cercopithecidae/cercopithecinae/macaca/macaca-fascicularis-1684.html">macaca fascicularis</a><li><a href="/topics/organisms/animals/chordata/vertebrates/mammals/rodentia/sciuridae-1750.html">sciuridae</a><li><a href="/topics/diagnostic/investigative/molecular/immunoassay/immunoenzyme/enzyme-linked-immunosorbent-assay-16546.html">enzyme linked immunosorbent assay</a><li><a href="/topics/diagnostic/investigative/drug/oral-administration-17538.html">oral administration</a><li><a href="/topics/physical/natural/biological/and/immunity/cellular-immunity-19533.html">cellular immunity</a><li><a href="/topics/chemicals/chemical/pharmacologic/physiological/immunologic/biological/immunologic-adjuvants-15686.html">immunologic adjuvants</a><li><a href="/topics/diagnostic/investigative/drug/intranasal-administration-17537.html">intranasal administration</a><li><a href="/topics/sociology/social/sociology/social/war/biological-warfare-20771.html">biological warfare</a><li><a href="/topics/diseases/animal/animal-disease-models-8536.html">animal disease models</a><li><a href="/topics/chemicals/pharmaceutical/dosage/colloids/aerosols-15873.html">aerosols</a><li><a href="/topics/chemicals/lipids/lipopolysaccharides/lipid-a-13516.html">lipid a</a><li><a href="/topics/diagnostic/investigative/epidemiologic/statistics/survival-analysis-17676.html">survival analysis</a><li><a href="/topics/diagnostic/investigative/immunologic/immunization/secondary-immunization-16630.html">secondary immunization</a><li><a href="/topics/sociology/social/criminology/crime/violence/terrorism/bioterrorism-20605.html">bioterrorism</a><li><a href="/topics/physical/natural/biological/anatomy/respiratory/lung-314.html">lung</a></ul></div></div><div class="left_box"><h2 class="left_box_header">Genomes and Genes</h2><div class="left_box_content"><ul><li><a href="/gene/mouse/stat4-20849.html">Stat4</a> <span class="more"><a href="http://www.labome.com/gene/20849">products</a></span><li><a href="/gene/mouse/stat6-20852.html">Stat6</a> <span class="more"><a href="http://www.labome.com/gene/20852">products</a></span><li><a href="/gene/mouse/ticam2-225471.html">Ticam2</a> <span class="more"><a href="http://www.labome.com/gene/225471">products</a></span><li><a href="/gene/mouse/tirap-117149.html">Tirap</a> <span class="more"><a href="http://www.labome.com/gene/117149">products</a></span><li><a href="/gene/mouse/ticam1-106759.html">Ticam1</a> <span class="more"><a href="http://www.labome.com/gene/106759">products</a></span><li><a href="/gene/mouse/tlr2-24088.html">Tlr2</a> <span class="more"><a href="http://www.labome.com/gene/24088">products</a></span><li><a href="/gene/mouse/tnf-21926.html">Tnf</a> <span class="more"><a href="http://www.labome.com/gene/21926">products</a></span><li><a href="/gene/mouse/tlr4-21898.html">Tlr4</a> <span class="more"><a href="http://www.labome.com/gene/21898">products</a></span><li><a href="/gene/mouse/cd14-12475.html">Cd14</a> <span class="more"><a href="http://www.labome.com/gene/12475">products</a></span><li><a href="/gene/mouse/rag1-19373.html">Rag1</a> <span class="more"><a href="http://www.labome.com/gene/19373">products</a></span><li><a href="/gene/mouse/nos2-18126.html">Nos2</a> <span class="more"><a href="http://www.labome.com/gene/18126">products</a></span><li><a href="/gene/mouse/myd88-17874.html">Myd88</a> <span class="more"><a href="http://www.labome.com/gene/17874">products</a></span><li><a href="/gene/mouse/md-2-17087.html">MD 2</a> <span class="more"><a href="http://www.labome.com/gene/17087">products</a></span><li><a href="/gene/mouse/dec-205-17076.html">DEC 205</a> <span class="more"><a href="http://www.labome.com/gene/17076">products</a></span><li><a href="/gene/mouse/ifngr1-15979.html">Ifngr1</a> <span class="more"><a href="http://www.labome.com/gene/15979">products</a></span><li><a href="/gene/mouse/ifng-15978.html">Ifng</a> <span class="more"><a href="http://www.labome.com/gene/15978">products</a></span><li><a href="/gene/yersinia/caf1-3077338.html">caf1</a> <span class="more"><a href="http://www.labome.com/gene/3077338">products</a></span></ul></div></div><div class="left_box"><h2 class="left_box_header">Species</h2><div class="left_box_content"><ul><li><a href="/species/cellular/metazoans/coelomata/craniata/teleostomi/tetrapods/theria/rodents/muroidea/mice/mouse-10090.html">mouse</a><li><a href="/species/cellular/gammaproteobacteria/yersinia/yersinia-pestis-632.html">Yersinia pestis</a></ul></div></div></div></td><td><div id="mid_td"><h1 id="mid_td_title">plague vaccine</h1><div class="mid_box"><h2 class="mid_box_header">Summary</h2><div class="mid_box_content"><div class="summary_box"><span class="summary_field">Summary: </span><span class="summary_content">A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.</span></div></div></div><div class="mid_box"><h2 class="mid_box_header">Top Publications</h2><div class="mid_box_content"><ol><li><a href="/bin/l.pl?link=puid_16476510"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery<div class="ol_sub">Vinita Tripathi<br>Department of Biochemistry, All India Institute of Medical Sciences AIIMS, Ansari Nagar, New Delhi 110029, India<br><i>Vaccine</i> 24:3279-89. 2006</div><li><a href="/bin/l.pl?link=pmcid_PMC2620661"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates<div class="ol_sub">Steven B Mizel<br>Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1064, USA<br><i>Clin Vaccine Immunol</i> 16:21-8. 2009</div><li><a href="/bin/l.pl?link=pmcid_PMC1111881"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Human immune response to a plague vaccine comprising recombinant F1 and V antigens<div class="ol_sub">E D Williamson<br>Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom<br><i>Infect Immun</i> 73:3598-608. 2005</div><li><a href="/bin/l.pl?link=pmcid_PMC3538834"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines<div class="ol_sub">Lauriane E Quenee<br>Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA<br><i>Vaccine</i> 29:6572-83. 2011</div><li><a href="/bin/l.pl?link=puid_19943765"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Prospects for new plague vaccines<div class="ol_sub">Valentina A Feodorova<br>Scientific and Research Institute for Medical and Veterinary Biotechnologies, Russia Switzerland, Branch in Saratov, 9 Proviantskaya Street, Box 1580, Saratov 410028, Russia<br><i>Expert Rev Vaccines</i> 8:1721-38. 2009</div><li><a href="/bin/l.pl?link=pmcid_PMC1698084"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation<div class="ol_sub">David A Chalton<br>Institute for Cell and Molecular Biosciences, University of Newcastle upon Tyne, Framlington Place, Newcastle NE2 4HH, United Kingdom<br><i>Infect Immun</i> 74:6624-31. 2006</div><li><a href="/bin/l.pl?link=puid_16980981"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response<div class="ol_sub">Sara W Montminy<br>Division of Infectious Diseases and Immunolbin/l.pl?link=puid_16980981"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide reogy, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA<br><i>Nat Immunol</i> 7:1066-73. 2006</div><li><a href="/bin/l.pl?link=puid_21670978"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Progress on plague vaccine development<div class="ol_sub">Jason A Rosenzweig<br>Department of Biology, Center for Bionanotechnology and Environmental Research CBER, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA<br><i>Appl Microbiol Biotechnol</i> 91:265-86. 2011</div><li><a href="/bin/l.pl?link=puid_19428836"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague<div class="ol_sub">Kei Amemiya<br>Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, United States<br><i>Vaccine</i> 27:2220-9. 2009</div><li><a href="/bin/l.pl?link=puid_17041851"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen<div class="ol_sub">Maria J Chiuchiolo<br>Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA<br><i>J Infect Dis</i> 194:1249-57. 2006</div></ol></div></div><div class="mid_box"><h2 class="mid_box_header">Research Grants</h2><div class="mid_box_content"><ol><li><a href="/grant/r01/ai/identification/of/identification-of-new-antigens-for-a-plague-vaccine-8474680.html">Identification of New Antigens for a Plague Vaccine</a><div class="ol_sub">Ashok K Chopra; Fiscal Year: 2013</div><li><a href="/grant/r01/ai/cell-mediated/protection/cell-mediated-protection-against-pneumonic-plague-8424303.html">Cell-mediated protection against pneumonic plague</a><div class="ol_sub">Jr Shiuan Lin; Fiscal Year: 2013</div><li><a href="/grant/r03/ai/evaluation/of/evaluation-of-ail-as-a-protective-immunogen-for-plague-8232034.html">Evaluation of Ail as a protective immunogen for plague</a><div class="ol_sub">Eric S Krukonis; Fiscal Year: 2012</div><li><a href="/grant/u01/ai/multivalent/plague/multivalent-plague--anthrax-vaccines-using-bacteriophage-t4-display-8435493.html">Multivalent Plague, Anthrax Vaccines Using Bacteriophage T4 Display</a><div class="ol_sub">Venigalla B Rao; Fiscal Year: 2013</div><li><a href="/grant/r01/ai/the/role/the-role-of-lps-tlr4-signaling-in-live-vaccine-induced-protective-responses-8441620.html">The role of LPS-TLR4 signaling in live vaccine-induced protective responses</a><div class="ol_sub">Egil Lien; Fiscal Year: 2013</div><li><a href="/grant/r01/ai/development/of/development-of-enabling-vector-antigen-expression-technology-for-an-orally-delive-8463454.html">Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive</a><div class="ol_sub">B Kim Lee Sim; Fiscal Year: 2013</div><li><a href="/grant/r21/ai/improved/plague/improved-plague-vaccine-by-targeting-dendritic-cell-subsets-7860350.html">Improved plague vaccine by targeting dendritic cell subsets</a><div class="ol_sub">Yoonkyung Do; Fiscal Year: 2010</div><li><a href="/grant/u01/ai/multi-gene/subunit/multi-gene-subunit-vaccine-platform-against-y--pestis-8129744.html">Multi-gene Subunit Vaccine Platform Against Y. pestis</a><div class="ol_sub">Shan Lu; Fiscal Year: 2011</div><li><a href="/grant/r44/ai/evaluation/and/evaluation-and-production-of-a-multivalent-adenoviral-plague-vaccine-8515916.html">Evaluation and Production of a Multivalent Adenoviral Plague Vaccine</a><div class="ol_sub">ERIC ROTHE; Fiscal Year: 2013</div><li><a href="/grant/r21/ai/role/of/role-of-yersinia-pestis-ail-in-yop-delivery-and-plague-8231326.html">Role of Yersinia pestis Ail in Yop delivery and plague</a><div class="ol_sub">Eric S Krukonis; Fiscal Year: 2012</div></ol></div></div></div></td><td><div id="right_td"><div class="right_box"><h2 class="right_box_header">Scientific Experts</h2><div class="right_box_content"><ul><li><a href="/expert/uk/porton/williamson/e-diane-williamson-561108.html">E Diane Williamson</a><li><a href="/expert/usa/arizona/alvarez/m-lucrecia-alvarez-921858.html">M Lucrecia Alvarez</a><li><a href="/expert/usa/trudeau/smiley/stephen-smiley-632588.html">STEPHEN SMILEY</a><li><a href="/expert/usa/dynport/fellows/patricia-fellows-1595557.html">Patricia Fellows</a><li><a href="/expert/do/yoonkyung-do-1584038.html">Yoonkyung Do</a><li><a href="/expert/usa/us/rocke/tonie-e-rocke-360077.html">Tonie E Rocke</a><li><a href="/expert/russia/laboratory/feodorova/v-a-feodorova-1156497.html">V A Feodorova</a><li><a href="/expert/uk/porton/eyles/jim-e-eyles-313909.html">Jim E Eyles</a><li><a href="/expert/usa/university/galen/j-e-galen-312715.html">J E Galen</a><li><a href="/expert/usa/dynport/price/jessica-l-price-2386646.html">Jessica L Price</a><li><a href="/expert/gauzere/b-a-gauzere-2173424.html">B A Gauzere</a><li><a href="/expert/usa/colorado/wolfe/lisa-l-wolfe-296381.html">Lisa L Wolfe</a><li><a href="/expert/usa/university/schneewind/olaf-schneewind-1128931.html">Olaf Schneewind</a><li><a href="/expert/usa/university/matson/jyl-s-matson-995949.html">Jyl S Matson</a><li><a href="/expert/usa/dynport/morris/stephen-r-morris-1120855.html">Stephen R Morris</a><li><a href="/expert/uk/porton/robinson/victoria-l-robinson-890677.html">Victoria L Robinson</a><li><a href="/expert/usa/arizona/branger/christine-g-branger-1158430.html">Christine G Branger</a><li><a href="/expert/usa/walter/powell/bradford-s-powell-1067481.html">Bradford S Powell</a><li><a href="/expert/usa/university/murphy/brian-s-murphy-1158431.html">Brian S Murphy</a><li><a href="/expert/usa/walter/goodin/jeremy-l-goodin-1576258.html">Jeremy L Goodin</a><li><a href="/expert/usa/texas/rosenzweig/jason-a-rosenzweig-1523714.html">Jason A Rosenzweig</a><li><a href="/expert/usa/us/matchett/marc-r-matchett-1501957.html">Marc R Matchett</a><li><a href="/expert/usa/bd/dsouza/ajit-joseph-m-d-souza-1455956.html">Ajit Joseph M D'souza</a><li><a href="/expert/uk/porton/vernazza/claire-vernazza-1326262.html">Claire Vernazza</a><li><a href="/expert/taiwan/tri-service/liu/wen-tssann-liu-1171030.html">Wen Tssann Liu</a><li><a href="/expert/usa/walter/amemiya/kei-amemiya-1323737.html">Kei Amemiya</a><li><a href="/expert/italy/university/del/g-del-prete-1255797.html">G Del Prete</a><li><a href="/expert/uk/porton/griffiths/gareth-d-griffiths-854261.html">Gareth D Griffiths</a><li><a href="/expert/usa/walter/reed/douglas-s-reed-331759.html">Douglas S Reed</a><li><a href="/expert/uk/porton/elvin/stephen-j-elvin-318506.html">Stephen J Elvin</a><li><a href="/expert/uk/porton/garmory/helen-s-garmory-312708.html">Helen S Garmory</a><li><a href="/expert/usa/wake/mizel/steven-mizel-285239.html">STEVEN MIZEL</a><li><a href="/expert/ireland/university/prentice/michael-b-prentice-278800.html">Michael B Prentice</a><li><a href="/expert/usa/walter/little/stephen-f-little-277473.html">Stephen F Little</a><li><a href="/expert/canada/id/jones/taff-jones-273211.html">Taff Jones</a><li><a href="/expert/germany/university/kaleta/e-f-kaleta-267487.html">E F Kaleta</a><li><a href="/expert/uk/university/alpar/h-o-alpar-253801.html">H O Alpar</a><li><a href="/expert/russia/state/anisimov/andrey-anisimov-861405.html">Andrey Anisimov</a><li><a href="/expert/uk/porton/griffin/kate-griffin-242531.html">Kate Griffin</a><li><a href="/expert/uk/porton/thomas/richard-j-thomas-340866.html">Richard J Thomas</a><li><a href="/expert/uk/porton/titball/r-w-titball-362338.html">R W Titball</a><li><a href="/expert/hawgood/barbara-j-hawgood-387021.html">Barbara J Hawgood</a><li><a href="/expert/usa/walter/anderson/g-w-anderson-813765.html">G W Anderson</a><li><a href="/expert/usa/center/zilinskas/r-a-zilinskas-773078.html">R A Zilinskas</a><li><a href="/expert/usa/us/creekmore/terry-e-creekmore-605516.html">Terry E Creekmore</a><li><a href="/expert/usa/johns/inglesby/t-v-inglesby-587735.html">T V Inglesby</a><li><a href="/expert/usa/national/welkos/s-welkos-583077.html">S Welkos</a><li>Shan Lu<li>Lauriane E Quenee<li>Eric S Krukonis<li>Ashok K Chopra<li>Jr">Terry E Creekmore</a><li><a href="/expert/usa/johns/inglesby/t-v-inglesby-587735.html">T V Inglesby</a><li><a href="/expert/usa/natio Shiuan Lin<li>Venigalla B Rao<li>Egil Lien<li>Xiaoyi Wang<li>ERIC ROTHE<li>George Lowell<li>B Kim Lee Sim<li>SUSAN STRALEY<li>DAN STINCHCOMB<li>CHRIS LENTZ<li>Richard Frothingham<li>Kathryn Sykes<li>Derek Elli<li>Ruifu Yang<li>Nancy A Ciletti<li>Jessica A Chichester<li>Zhizhen Qi<li>Zuyun Wang<li>Hitoki Yamanaka<li>Shixia Wang<li>Michelle A Parent<li>Qingwen Zhang<li>Baizhong Cui<li>Hu Wang<li>Yonghai Yang<li>D N Rao<li>Jorge E Osorio<li>Yehuda Flashner<li>Claire A Cornelius<li>Vidadi Yusibov<li>Anasuya Chattopadhyay<li>Vadim Mett<li>Frank M Szaba<li>Haim Grosfeld<li>Lawrence W Kummer<li>Dongsheng Zhou<li>Svetlana Senina<li>Julie A Musson<li>Kwang Chul Kwon</ul></div></div></div></td></tr>
	</table>
	
	<div id="sup_separator"> </div><div id="supplement"><h2 id="sup_head_title">Detail Information</h2><div class="super_box"><h3 class="super_box_header">Publications<span class="bar_note">143 found, 100 shown here</span></h3><div class="super_box_content"><ol><li><a href="/bin/l.pl?link=puid_16476510"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery<div class="ol_sub">Vinita Tripathi<br>Department of Biochemistry, All India Institute of Medical Sciences AIIMS, Ansari Nagar, New Delhi 110029, India<br><i>Vaccine</i> 24:3279-89. 2006</div><div class="excerpt">..There is a need for an improved <b>plague vaccine</b> that may overcome the limitation of presently available whole cell vaccine...</div><li><a href="/bin/l.pl?link=pmcid_PMC2620661"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates<div class="ol_sub">Steven B Mizel<br>Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157 1064, USA<br><i>Clin Vaccine Immunol</i> 16:21-8. 2009</div><div class="excerpt">..On the basis of our results, we believe that flagellin-F1-V is an outstanding candidate for evaluation in studies with humans...</div><li><a href="/bin/l.pl?link=pmcid_PMC1111881"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Human immune response to a plague vaccine comprising recombinant F1 and V antigens<div class="ol_sub">E D Williamson<br>Dstl Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom<br><i>Infect Immun</i> 73:3598-608. 2005</div><div class="excerpt">The human immune response to a new recombinant <b>plague vaccine</b>, comprising recombinant F1 (rF1) and rV antigens, has been assessed during a phase 1 safety and immunogenicity trial in healthy volunteers...</div><li><a href="/bin/l.pl?link=pmcid_PMC3538834"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines<div class="ol_sub">Lauriane E Quenee<br>Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA<br><i>Vaccine</i> 29:6572-83. 2011</div><div class="excerpt">..A US Food and Drug Administration (FDA)-licensed <b>plague vaccine</b> is currently not available. Vaccine developers have focused on two subunits of Y...</div><li><a href="/bin/l.pl?link=puid_19943765"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Prospects for new plague vaccines<div class="ol_sub">Valentina A Feodorova<br>Scientific and Research Institute for Medical and Veterinary Biotechnologies, Russia Switzerland, Branch in Saratov, 9 Proviantskaya Street, Box 1580, Saratov 410028, Russia<br><i>Expert Rev Vaccines</i> 8:1721-38. 2009</div><div class="excerpt">..The regulatory problems inherent in licensing vaccines for which efficacy data are unavailable and their possible solutions are discussed herein...</div><li><a href="/bin/l.pl?link=pmcid_PMC1698084"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation<div class="ol_sub">David A Chalton<br>Institute for Cell and Molecular Biosciences, University of Newcastle upon Tyne, Framlington Place, Newcastle NE2 4HH, United Kingdom<br><i>Infect Immun</i> 74:6624-31. 2006</div><div class="excerpt">..The use of circular permutation in vaccine design has not been reported previously...</div><li><a href="/bin/l.pl?link=puid_16980981"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response<div class="ol_sub">Sara W Montminy<br>Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA<br><i>Nat Immunol</i> 7:1066-73. 2006</div><div class="excerpt">..pestis virulence. Evading TLR4 activation by lipid A alteration may contribute to the virulence of various Gram-negative bacteria...</div><li><a href="/bin/l.pl?link=puid_21670978"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Progress on plague vaccine development<div class="ol_sub">Jason A Rosenzweig<br>Department of Biology, Center for Bionanotechnology and Environmental Research CBER, Texas Southern University, 3100 Cleburne Street, Houston, TX 77004, USA<br><i>Appl Microbiol Biotechnol</i> 91:265-86. 2011</div><div class="excerpt">..This review article will describe the current vaccine candidates being evaluated in various model systems and provide an overall summary on the progress of this important endeavor...</div><li><a href="/bin/l.pl?link=puid_19428836"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague<div class="ol_sub">Kei Amemiya<br>Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702, United States<br><i>Vaccine</i> 27:2220-9. 2009</div><div class="excerpt">The current U.S. Department of Defense candidate <b>plague vaccine</b> is a fusion between two Yersinia pestis proteins: the F1 capsular protein, and the low calcium response (Lcr) V-protein...</div><li><a href="/bin/l.pl?link=puid_17041851"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen<div class="ol_sub">Maria J Chiuchiolo<br>Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA<br><i>J Infect Dis</i> 194:1249-57. 2006</div><div class="excerpt">..These observations suggest that an Ad gene-transfer vector expressing V antigen is a candidate for development of an effective anti-<b>plague vaccine</b>.</div><li><a href="/bin/l.pl?link=puid_19786842"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Plague vaccines and the molecular basis of immunity against Yersinia pestis<div class="ol_sub">Lauriane E Quenee<br>Department of Microbiology, University of Chicago, Chicago, IL, USA<br><i>Hum Vaccin</i> 5:817-23. 2009</div><div class="excerpt">..Several subunit vaccines, for example rF1+rV (rYP002), rF1V or rV10, are being developed to generate plague protection in humans. Efficacy testing and licensure for human use requires the establishment of correlates for plague immunity...</div><li><a href="/bin/l.pl?link=pmcid_PMC2365752"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Current challenges in the development of vaccines for pneumonic plague<div class="ol_sub">Stephen T Smiley<br>Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA<br><i>Expert Rev Vaccines</i> 7:209-21. 2008</div><div class="excerpt">..Extensively antibiotic-resistant Y. pestis strains exist and we currently lack a safe and effective pneumonic <b>plague vaccine</b>. These facts raise concern that Y. pestis may be exploited as a bioweapon...</div><li><a href="/bin/l.pl?link=puid_15308359"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague<div class="ol_sub">Shixia Wang<br>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Lazare Research Building, Worcester, MA 01605, USA<br><i>Vaccine</i> 22:3348-57. 2004</div><div class="excerpt">..These results support that optimized DNA vaccines have the potential to protect against bacterial pathogens than is generally recognized...</div><li><a href="/bin/l.pl?link=puid_11838226"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>A baiting system for delivery of an oral plague vaccine to black-tailed prairie dogs<div class="ol_sub">Terry E Creekmore<br>U S Geological Service, National Wildlife Health Center, 6006 Schroeder Road, Madison, Wisconsin 53711, USA<br><i>J Wildl Dis</i> 38:32-9. 2002</div><div class="excerpt">..October 1999 to identify bait preference, biomarker efficacy, and bait acceptance rates for delivering an oral <b>plague vaccine</b> to black-tailed prairie dogs (Cynomys ludovicianus)...</div><li><a href="/bin/l.pl?link=puid_21055471"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Purification and characterization of a recombinant Yersinia pestis V-F1 "Reversed" fusion protein for use as a new subunit vaccine against plague<div class="ol_sub">Jeremy L Goodin<br>Bacteriology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA<br><i>Protein Expr Purif</i> 76:136-44. 2011</div><div class="excerpt">..F1S-V-F1 polymerization characteristics were comparable to the native F1. The purified F1S-V-F1 protein appeared equivalent to F1-V in its ability to be recognized by neutralizing antibodies...</div><li><a href="/bin/l.pl?link=puid_15474730"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Immunisation against plague by transcutaneous and intradermal application of subunit antigens<div class="ol_sub">J E Eyles<br>Biomedical Sciences, Dstl, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK<br><i>Vaccine</i> 22:4365-73. 2004</div><div class="excerpt">..These data suggest that transcutaneous immunisation may be a simple and non-invasive method for immunising individuals against plague...</div><li><a href="/bin/l.pl?link=pmcid_PMC3560410"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice<div class="ol_sub">Joseph N Brewoo<br>Inviragen, Inc, Madison, WI 53719, USA<br><i>Vaccine</i> 28:5891-9. 2010</div><div class="excerpt">..Based on their safety and efficacy in mice, these MVA/Y. pestis recombinants are candidates for further development as biodefense and public health vaccines...</div><li><a href="/bin/l.pl?link=pmcid_PMC2811967"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague<div class="ol_sub">Jeremy L Goodin<br>Bacteriology Division, U S Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA<br><i>Protein Expr Purif</i> 53:63-79. 2007</div><div class="excerpt">..pestis CO92. Thus, vaccination with F1-V monomer and multimeric forms resulted in significant, and essentially equivalent, protection...</div><li><a href="/bin/l.pl?link=puid_22442294"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>The natural history and incidence of Yersinia pestis and prospects for vaccination<div class="ol_sub">E D Williamson<br>Biomedical Sciences, Dstl Porton Down, Salisbury SP4 0JQ, UK<br><i>J Med Microbiol</i> 61:911-8. 2012</div><div class="excerpt">..The considerable challenges in achieving a vaccine which is licensed for human use and which will comprehensively protect against this serious human pathogen are assessed...</div><li><a href="/bin/l.pl?link=puid_22846964"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Sylvatic plague vaccine: a new tool for conservation of threatened and endangered species?<div class="ol_sub">Rachel C Abbott<br>US Geological Survey, National Wildlife Health Center, Madison, WI 53711, USA<br><i>Ecohealth</i> 9:243-50. 20alt="ncbi"> </a>Sylvatic plague vaccine: a new tool for conservation of thr12</div><div class="excerpt">..strategy would be similarly enhanced with the addition of a cost-effective, bait-delivered, sylvatic <b>plague vaccine</b> for prairie dogs...</div><li><a href="/bin/l.pl?link=pmcid_PMC2663150"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols<div class="ol_sub">Richard J Thomas<br>Defence Science and Technology Laboratory Dstl, Porton Down, Salisbury, Wiltshire SP40JQ, United Kingdom<br><i>Infect Immun</i> 77:1315-23. 2009</div><div class="excerpt">..Although there were major differences in pathogenesis, the recombinant F1 and V antigen vaccine and ciprofloxacin protected against plague infections caused by small- and large-particle aerosols...</div><li><a href="/bin/l.pl?link=pmcid_PMC3571283"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Evaluation of protective potential of Yersinia pestis outer membrane protein antigens as possible candidates for a new-generation recombinant plague vaccine<div class="ol_sub">Tatiana E Erova<br>Departments of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA<br><i>Clin Vaccine Immunol</i> 20:227-38. 2013</div><div class="excerpt">..Together, the addition of Y. pestis outer membrane proteins to a new-generation recombinant vaccine could provide protection against a wide variety of Y. pestis strains...</div><li><a href="/bin/l.pl?link=puid_20920572"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)<div class="ol_sub">Patricia Fellows<br>DynPort Vaccine Company, A CSC Company, 64 Thomas Johnson Drive, Frederick, MD 21702, United States<br><i>Vaccine</i> 28:7748-56. 2010</div><div class="excerpt">..evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant <b>plague vaccine</b> (rF1V) to protect na√Øve Swiss Webster mice against pneumonic plague...</div><li><a href="/bin/l.pl?link=puid_19837288"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Plague<div class="ol_sub">E D Williamson<br>Defence Science and Technology Laboratory Dstl, Porton Down, Salisbury, Wilts SP4 0JQ, UK<br><i>Vaccine</i> 27:D56-60. 2009</div><div class="excerpt">..This paper reviews the progress towards an improved vaccine for plague and assesses the likely impact of a prophylactic vaccine for bubonic and pneumonic plague...</div><li><a href="/bin/l.pl?link=pmcid_PMC3075555"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>IL-17 contributes to wards an improved vaccine for plague and assescell-mediated defense against pulmonary Yersinia pestis infection<div class="ol_sub">Jr Shiuan Lin<br>Trudeau Institute, Saranac Lake, NY 12983, USA<br><i>J Immunol</i> 186:1675-84. 2011</div><div class="excerpt">..pestis challenge, and we suggest that pneumonic plague vaccines should aim to induce mixed type 1 and type 17 cellular responses...</div><li><a href="/bin/l.pl?link=pmcid_PMC1905224"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model<div class="ol_sub">E D Williamson<br>DERA, Chemical and Biological Defence Sector, Salisbury, UK<br><i>Clin Exp Immunol</i> 116:107-14. 1999</div><div class="excerpt">..05) with protection. The titres of IgG1 in vaccinated mice which correlated with 90%, 50% and 10% protection have been determined and provide a useful model to predict vaccine efficacy in man...</div><li><a href="/bin/l.pl?link=pmcid_PMC2043315"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine<div class="ol_sub">Sarah S Bubeck<br>Department of Microbiology and Immunology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229, USA<br><i>Clin Vaccine Immunol</i> 14:1235-8. 2007</div><div class="excerpt">..When it is used as a live, attenuated vaccine, CO92 delta yopH provides a high degree of protection from parental and respiratory challenge with Y. pestis CO92...</div><li><a href="/bin/l.pl?link=puid_16610337"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>The anti-plague system and the Soviet biological warfare program<div class="ol_sub">Raymond A Zilinskas<br>Monterey Institute of International Studies, Center for Nonproliferation Studies, Monterey, California 93940, USA<br><i>Crit Rev Microbiol</i> 32:47-64. 2006</div><div class="excerpt">..This article describes the anti-plague system's activities relevant to both aspects of the Soviet Union's biological warfare program, offense and defense, and analyzes its contributions to each...</div><li><a href="/bin/l.pl?link=puid_19786138"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>N255 is a key residue for recognition by a monoclonal antibody which protects against Yersinia pestis infection<div class="ol_sub">Jim Hill<br>Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK<br><i>Vaccine</i> 27:7073-9. 2009</div><div class="excerpt">..3 protects by binding to LcrV(Ype) and interfering with protein-protein interactions necessary for type three secretion...</div><li><a href="/bin/l.pl?link=pmcid_PMC1828512"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Vaccination with liverpt">..3 protects by binding to LcrV(Ype) and Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection<div class="ol_sub">Alexander V Philipovskiy<br>Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA<br><i>Infect Immun</i> 75:878-85. 2007</div><div class="excerpt">..To aid the development of a safe and effective <b>plague vaccine</b>, we are investigating roles for T cells during defense against Y. pestis infection...</div><li><a href="/bin/l.pl?link=pmcid_PMC2346721"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Yersinia pestis caf1 variants and the limits of plague vaccine protection<div class="ol_sub">Lauriane E Quenee<br>Department of Microbiology, University of Chicago, Chicago, Illinois 60637, USA<br><i>Infect Immun</i> 76:2025-36. 2008</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=puid_12922126"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protective efficacy of a fully recombinant plague vaccine in the guinea pig<div class="ol_sub">S M Jones<br>Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, UK<br><i>Vaccine</i> 21:3912-8. 2003</div><div class="excerpt">..Cross-protection of the mouse with guinea pig IgG suggests that the recognition of neutralising epitopes in the F1 and V proteins is conserved between these two species...</div><li><a href="/bin/l.pl?link=pmcid_PMC2864640"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells<div class="ol_sub">Yoonkyung Do<br>Laboratory of Cellular Physiology and Immunology and Chris Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York 10065 6399, USA<br><i>Eur J Immunol</i> 38:20-9. 2008</div><div class="excerpt">..This study sets the stage for the analysis of functional roles of IFN-gamma-producing T cells in Y. pestis infection...</div><li><a href="/bin/l.pl?link=puid_11457543"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Vaccination against bubonic and pneumonic plague<div class="ol_sub">R W Titball<br>Defence Evaluation and Research Agency, CBD Porton Down, Salisbury, SP4 0JQ, Wilts, UK<br><i>Vaccine</i> 19:4175-84. 2001</div><div class="excerpt">..A killed whole cell <b>plague vaccine</b> has been used in the past, but recent studies in animals have shown that this vaccine offers poor protection ..</div><li><a href="/bin/l.pl?link=pmcid_PMC2804960"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Immune defense against pneumonic plague<div class="ol_sub">Stephen T Smiley<br>Trudeau Institute, Saranac Lake, NY 12983, USA<br><i>Immunol Rev</i> 225:256-71. 2008</div><div class="excerpt">..Here, I review the immunology of pneumonic plague, focusing on evidence that humoral and cellular defense mechanisms collaborate to defend against pulmonary Y. pestis infection...</div><li><a href="/bin/l.pl?link=pmcid_PMC2583586"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague<div class="ol_sub">Claire A Cornelius<br>Department of Microbiology, University of Chicago, Chicago, Illinois 60637, USA<br><i>Infect Immun</i> 76:5588-97. 2008</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=pmcid_PMC2577737"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine<div class="ol_sub">Christina L Airhart<br>Department of Microbiology, Molecular Biology, and Biochemistry, University of Idaho, 142 Life Science, Moscow, ID 83844 3052, United States<br><i>Vaccine</i> 26:5554-61. 2008</div><div class="excerpt">..This intranasal vaccine showed 90% protection in Sprague-Dawley rats challenged with 1000 LD50. We conclude that lipid A mimetics are highly effective adjuvants for an i.n. <b>plague vaccine</b>.</div><li><a href="/bin/l.pl?link=pmcid_PMC2628553"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection<div class="ol_sub">Anasuya Chattopadhyay<br>Department of Pathology, Yale University School of Medicine, 310 Cedar Street LH 315, New Haven, CT 06510, USA<br><i>Vaccine</i> 26:6329-37. 2008</div><div class="excerpt">We have developed an experimental recombinant vesicular stomatitis virus (VSV) vectored <b>plague vaccine</b> expressing a secreted form of Yersinia pestis low calcium response protein V (LcrV) from the first position of the VSV genome...</div><li><a href="/bin/l.pl?link=pmcid_PMC321629"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Generation of Yersinia pestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates<div class="ol_sub">Yehuda Flashner<br>Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, 74100, Israel<br><i>Infect Immun</i> 72:908-15. 2004</div><div class="excerpt">..This Kimberley53pcm mutant was superior to the EV76 live vaccine strain because it induced 10- to 100-fold-higher antibody titers to the protective V and F1 antigens and because it conferred efficacious protective immunity...</div><li><a href="/bin/l.pl?link=pmcid_PMC2703157"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Clinical and pathologic features of cynomolgus macaques (Macaca fascicularis) infected with aerosolized Yersinia pestis<div class="ol_sub">Roger Van Andel<br>Lovelace Respiratory Research Institute, Albuquerque, NM, USA<br><i>Comp Med</i> 58:68-75. 2008</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=puid_21039737"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Comparison of immunological responses of plague vaccines F1+rV270 and EV76 in Chinese-origin rhesus macaque, Macaca mulatta<div class="ol_sub">Y Qiu<br>Laboratory of Analytical Microbiology, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China<br><i>Scand J Immunol</i> 72:425-33. 2010</div><div class="excerpt">..pestis challenge by subcutaneous route in Chinese-origin rhesus macaques...</div><li><a href="/bin/l.pl?link=puid_19779739"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Humoral immune responses and protective efficacy of sequential B- and T-cell epitopes of V antigen of Yersinia pestis by intranasal immunization in microparticles<div class="ol_sub">Jayaprakash Babu Uppada<br>Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India<br><i>Med Microbiol Immunol</i> 198:247-56. 2009</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=pmcid_PMC174416"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis<div class="ol_sub">G W Anderson<br>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702 5011, USA<br><i>Infect Immun</i> 64:4580-5. 1996</div><div class="excerpt">..This work demonstrates that a subunit <b>plague vaccine</b> formulated for human use provides significant protection against bubonic plague caused by an F1- strain (C12) ..</div><li><a href="/bin/l.pl?link=pmcid_PMC2822060"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Amino acid residues 196-225 of LcrV represent a plague protective epitope<div class="ol_sub">Lauriane E Quenee<br>Department of Microbiology, University of Chicago, 920 East 58th Street, Chicago, IL 60637, USA<br><i>Vaccine</i> 28:1870-6. 2010</div><div class="excerpt">..These results identify LcrV residues 196-225 as a linear epitope that is recognized by the murine immune system to confer plague protection...</div><li><a href="/bin/l.pl?link=pmcid_PMC1273885"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Cell-mediated protection against pulmonary Yersinia pestis infection<div class="ol_sub">Michelle A Parent<br>Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA<br><i>Infect Immun</i> 73:7304-10. 2005</div><div class="excerpt">..These findings establish that vaccine-primed cellular immunity can protect against pulmonary Y. pestis infection and suggest that vaccines promoting both humoral and cellular immunity will most effectively combat pneumonic plague...</div><li><a href="/bin/l.pl?link=puid_10807389"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense<div class="ol_sub">T V Inglesby<br>Center for Civilian Biodefense Studies, Johns Hopkins University Schools of Medicine, Baltimore, MD 21202, USA<br><i>JAMA</i> 283:2281-90. 2000</div><div class="excerpt">..The Working Group on Civilian Biodefense has developed consensus-based recommendations for measures to be taken by medical and public health professionals following the use of plague as a biological weapon against a civilian population...</div><li><a href="/bin/l.pl?link=puid_15308361"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Defining the genome content of live plague vaccines by use of whole-genome DNA microarray<div class="ol_sub">Dongsheng Zhou<br>Laboratory of Analytical Microbiology, National Center for Biomedical Analysis, Army Center for Microbial Detection and Research, Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences AMMS, Beijing 100071, PR China<br><i>Vaccine</i> 22:3367-74. 2004</div><div class="excerpt">..The whole-genome DNA microarray also provides an ideal tool to perform the pre-evaluation of a vaccine strain for its high throughput to determine the genomic features essential or unallowable for the live vaccines...</div><li><a href="/bin/l.pl?link=puid_17107769"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates<div class="ol_sub">E D Williamson<br>Defence Science and Technology Laboratory, Porton Down, Salisbury, Wilts UK SP4 0JQ, UK<br><i>Microb Pathog</i> 42:11-21. 2007</div><div class="excerpt">..Serum samples from representative macaques within this time period also inhibited the Yersinia-mediated cytotoxicity of J774 macrophages in a qualitative in vitro assay of type three secretion...</div><li><a href="/bin/l.pl?link=puid_16840777"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes<div class="ol_sub">Julie A Musson<br>Musculoskeletal Research Group, Institute of Cellular Medicine, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2 4HH, United Kingdom<br><i>J Biol Chem</i> 281:26129-35. 2006</div><div clalymphocytes<div class="ol_sub">Julie A Musson<br>Musculoskeletal Research Group, Institute of Cellular Medicine, University of Newcastle, Framlington Place, Newcastle upon Tyne NE2ss="excerpt">....</div><li><a href="/bin/l.pl?link=puid_15734068"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Effect of homologous and heterologous prime-boost on the immune response to recombinant plague antigens<div class="ol_sub">Audrey Glynn<br>Department of Microbiology and Immunology, Program in Molecular Pathogenesis and Immunity, 1430 Tulane Avenue, Tulane University Health Sciences Center, New Orleans, LA 70112, USA<br><i>Vaccine</i> 23:1957-65. 2005</div><div class="excerpt">..These studies provide important insights into the development of new-generation biodefense vaccines...</div><li><a href="/bin/l.pl?link=puid_17287055"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>A plant-produced plague vaccine candidate confers protection to monkeys<div class="ol_sub">Vadim Mett<br>Fraunhofer USA Center for Molecular Biotechnology, 9 Innovation Way, Suite 200, Newark, DE 19711, USA<br><i>Vaccine</i> 25:3014-7. 2007</div><div class="excerpt">..pestis. This study clearly demonstrates the efficacy of a plant-produced <b>plague vaccine</b> candidate in a primate model.</div><li><a href="/bin/l.pl?link=puid_20079562"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270<div class="ol_sub">Zhizhen Qi<br>Qinghai Institute for Endemic Disease Prevention and Control of Qinghai Province, Xining 811602, China<br><i>Vaccine</i> 28:1655-60. 2010</div><div class="excerpt">..The subunit vaccine and EV76 vaccine are able to provide protection for animals against Y. pestis challenge, but the subunit vaccines have obvious advantages over EV76 in terms of safety of use...</div><li><a href="/bin/l.pl?link=puid_12798649"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague<div class="ol_sub">Helen S Garmory<br>Dstl Chemical and Biological Sciences, Porton Down, Salisbury SP4 0JQ, UK<br><i>Vaccine</i> 21:3051-7. 2003</div><div class="excerpt">..pestis V antigen as a candidate oral <b>plague vaccine</b>. SL3261 was transformed with the expression plasmid pTrc-LcrV, containing the lcrV gene encoding V antigen...</div><li><a href="/bin/l.pl?link=puid_16243411"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection<div class="ol_sub">Taff Jones<br>ID Biomedical Corporation of Quebec, 525 Cartier Blvd West, Laval, Montreal, Que, Canada H7V 3S8<br><i>Vaccine</i> 24:1625-32. 2006</div><div class="excerpt">..Mice immunized in against lethal aerosolized plague infection<tranasally with Protollin-F1-V were 100% protected against aerosol challenge with 170 LD50 of Y. pestis and 80% against 255 LD50...</div><li><a href="/bin/l.pl?link=pmcid_PMC1539636"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV<div class="ol_sub">Kristin L Debord<br>Department of Microbiology, University of Chicago, 920 E 58th Street, Chicago, Illinois 60637, USA<br><i>Infect Immun</i> 74:4910-4. 2006</div><div class="excerpt">..Immunization with rV10 generates robust antibody responses that protect mice against bubonic plague and pneumonic plague, suggesting that rV10 may serve as an improved <b>plague vaccine</b>.</div><li><a href="/bin/l.pl?link=pmcid_PMC1479272"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection<div class="ol_sub">Michelle A Parent<br>Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA<br><i>Infect Immun</i> 74:3381-6. 2006</div><div class="excerpt">..pestis challenge. These observations strongly suggest that plague vaccines should striss="ol_sub">Michelle A Parent<br>Trudeau Institute, 154 Algonquin Avenue, Saranac Lake, NY 12983, USA<br><i>Infect Immun</i> 74:3381-6. 2006</div><divve to maximally prime both cellular and humoral immunity...</div><li><a href="/bin/l.pl?link=puid_18263816"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Vaccination with F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against plague upon oral challenge with Yersinia pestis<div class="ol_sub">Tonie E Rocke<br>US Geological Survey, National Wildlife Health Center, 6006 Schroeder Road, Madison, WI 53711, USA<br><i>J Wildl Dis</i> 44:1-7. 2008</div><div class="excerpt">..High titers to both F1 and V (mean reciprocal titers of 18,552 and 99,862, respectively) were found in all vaccinates up to 2 yr postvaccination, whereas seven control animals remained antibody negative throughout the same time period...</div><li><a href="/bin/l.pl?link=puid_17869388"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity<div class="ol_sub">Jim E Eyles<br>Biomedical Sciences Department, Dstl, Porton Down, Wiltshire SP4 0JQ, UK<br><i>Vaccine</i> 25:7301-6. 2007</div><div class="excerpt">..pestis: intradermal injection might therefore be considered as a potential minimally invasive method of <b>plague vaccine</b> administration. These data have implications for the design of therapeutic strategies against plague infection.</div><li><a href="/bin/l.pl?link=puid_17913308"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs<div class="ol_sub">V A Feodorova<br>Russian State Anti Plague Research Institute Microbe, 46 Universitetskaya Street, Saratov 410005, Russia<br><i>Vaccine</i> 25:7620-8. 2007</div><div class="excerpt">..5 x 10(4) CFU) of this vaccine. A subcutaneous challenge with 2000 median lethal doses (equal to 20,000 CFU) of fully virulent Y. pestis 231 strain, is a 6-10-fold higher dose than that which the EV NIIEG itself can protect against...</div><li><a href="/bin/l.pl?link=puid_17966434"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Cell-mediated defense against Yersinia pestis infection<div class="ol_sub">Stephen T Smiley<br>Trudeau Institute, Saranac Lake, NY, USA<br><i>Adv Exp Med Biol</i> 603:376-86. 2007</div><div class="excerpt">..To counter that possibility, it is essential that we develop a safe and effective pneumonic <b>plague vaccine</b>. Recent studies suggest that the leading vaccine candidate, which primarily stimulates antibody-mediated ..</div><li><a href="/bin/l.pl?link=puid_17966435"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Oral vaccination with different antigens from Yersinia pestis KIM delivered by live attenuated Salmonella typhimurium elicits a protective immune response against plague<div class="ol_sub">Christine G Branger<br>Center for Infectious Diseases and Vaccinology, The Biodesign Institute, Arizona State University, Tempe, USA<br><i>Adv Exp Med Biol</i> 603:387-99. 2007</div><div class="excerpt">..This finding should facilitate the design and development of a new generation of vaccines against Y. pestis...</div><li><a href="/bin/l.pl?link=puid_17966436"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Yersinia pestis YadC: a novel vaccine candidate against plague<div class="ol_sub">Brian S Murphy<br>Department of Internal Medicine, University of Kentucky, Lexington, USA<br><i>Adv Exp Med Biol</i> 603:400-14. 2007</div><div class="excerpt">..This mixed Thl/Th2 response suggests that YadC's protection may involve a different adaptive immune response than the LcrV protein that currently is part of plague vaccines...</div><li><a href="/bin/l.pl?link=puid_17101198"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague<div class="ol_sub">E D Williamson<br>Dstl Porton Down, Salisbury, Wilts SP4 0JQ, UK<br><i>Vaccine</i> 25:1142-8. 2007</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=pmcid_PMC2573372"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Vaccination of mice with a Yop translocon complex elicits antibodies that are protective against infection with F1- Yersinia pestis<div class="ol_sub">Maya I Ivanov<br>Center for Infectious Diseases, SUNY Stony Brook, Stony Brook, NY 11794 5222, USA<br><i>Infect Immun</i> 76:5181-90. 2008</div><div class="excerpt">..pestis. These results indicate that anti-translocon antibodies can be used as immunotherapy to treat infections by F1(-) Y. pestis...</div><li><a href="/bin/l.pl?link=pmcid_PMC2546814"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague<div class="ol_sub">Hitoki Yamanaka<br>Veterinary Molecular Biology, Montana State University, Bozeman, Montana 59717 3610, USA<br><i>Infect Immun</i> 76:4564-73. 2008</div><div class="excerpt">..These results show that IL-12 can be used as a molecular adjuvant to enhance protective immunity against pneumonic plague, but in a dose-dependent fashion...</div><li><a href="/bin/l.pl?link=puid_18030785"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>[Prophylactic use of ceftriaxone in combination with F I antigen immunization in studies on uninbred albino mice infected by Yersinia pestis. Antiplague immunity development]<div class="ol_sub">I V Ryzhko<br><i>Antibiot Khimioter</i> 51:8-12. 2006</div><div class="excerpt">..pestis EV NIIEG (II 1.2x10(5)). The results of the study are indicative of the prospective use of subsingle vaccines of the new generation based on F I antigen for combined specific and urgent prophylaxis...</div><li><a href="/bin/l.pl?link=pmcid_PMC2288748"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice<div class="ol_sub">Shixia Wang<br>Laboratory of Nucleic Acid Vaccines, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605 2397, USA<br><i>Vaccine</i> 26:1664-74. 2008</div><div class="excerpt">..These results demonstrate that DNA immunization is effective in screening, optimizing and comparing optimal antigen designs and immunogenicity of candidate antigens for the development of a subunit-based <b>plague vaccine</b>.</div><li><a href="/bin/l.pl?link=puid_17966437"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protective immunity against plague<div class="ol_sub">Claire Cornelius<br>Department of Microbiology, University of Chicago, IL, USA<br><i>Adv Exp Med Biol</i> 603:415-24. 2007</div><div class="excerpt">..More research is required to examine the molecular mechanisms of vaccine protection affo class="ol_sub">Claire Cornelius<br>Department of Microbiology, University of Chicago, IL, USA<br><i>Adv Exp Med Biol</i> 603:415-24. 2007</div><div class="excerpt">..More research is required to examine the molecular mechanisms of vaccine rded by surface protein antigens and to decipher the host mechanisms responsible for vaccine success...</div><li><a href="/bin/l.pl?link=pmcid_PMC375218"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Flea-borne transmission model to evaluate vaccine efficacy against naturally acquired bubonic plague<div class="ol_sub">Clayton O Jarrett<br>Laboratory of Human Bacterial Pathogenesis, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana 59840, USA<br><i>Infect Immun</i> 72:2052-6. 2004</div><div class="excerpt">..The model provides a means to directly assess the efficacy of new vaccines to prevent naturally acquired bubonic plague and to study events at the vector-host interface that lead to dissemination and disease...</div><li><a href="/bin/l.pl?link=puid_16768208"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>[Construction of variants of Yersinia pestis EV76 (RIEG line) vaccine strain differing in antibiotic resistance spectra with stage-by-stage transduction of R-transposons]<div class="ol_sub">A S Cherniavskaia<br><i>Antibiot Khimioter</i> 50:13-7. 2005</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=pmcid_PMC387406"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Intraspecific diversity of Yersinia pestis<div class="ol_sub">Andrey P Anisimov<br>Department of Infectious Diseases, State Research Center for Applied Microbiology, 142279 Obolensk, Serpukhov District, Moscow Region, Russia<br><i>Clin Microbiol Rev</i> 17:434-64. 2004</div><div class="excerpt">..pestis strains based on genetic and phenotypic variation and show that there is a high level of diversity in these strains not reflected by ones obtained from sylvatic areas and patients in the Americas...</div><li><a href="/bin/l.pl?link=pmcid_PMC517477"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine<div class="ol_sub">Jordan S Mencher<br>Wildlife Science Group, University of Washington, Seattle, Washington, USA<br><i>Infect Immun</i> 72:5502-5. 2004</div><div class="excerpt">..Antibody titers against Y. pestis F1 antigen increased significantly (P &lt; 0.01) in vaccinees, and their survival was significantly higher upon challenge with Y. pestis than that of negative controls (P &lt; 0.01)...</div><li><a href="/bin/l.pl?link=puid_15458778"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague<div class="ol_sub">Stephen J Elvin<br>Defence Science and Technology Laboratories, Porton Dowpuid_15458778"><img src="/img/ncbi.gif" classn, Salisbury SP4 0JQ, UK<br><i>Microb Pathog</i> 37:177-84. 2004</div><div class="excerpt">..It appears therefore that type 1 immune mechanisms, activated following Stat 4 phosphorylation, are essential in protection against plague...</div><li><a href="/bin/l.pl?link=puid_16145573"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>A plague upon the phagocytes<div class="ol_sub">Frank R Deleo<br><i>Nat Med</i> 11:927-8. 2005</div><li><a href="/bin/l.pl?link=puid_16442673"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Plant-made subunit vaccine against pneumonic and bubonic plague is orally immunogenic in mice<div class="ol_sub">M Lucrecia Alvarez<br>Center for Infectious Diseases and Vaccinology CIDV, The Biodesign Institute at Arizona State University, 1001 South McAllister Avenue, Tempe, AZ 85287 4501, USA<br><i>Vaccine</i> 24:2477-90. 2006</div><div class="excerpt">..We developed a novel production and delivery system for a <b>plague vaccine</b> of a Y. pestis F1-V antigen fusion protein expressed in tomato...</div><li><a href="/bin/l.pl?link=pmcid_PMC1360354"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis<div class="ol_sub">Anna N Honko<br>Department of Microbiology and Immunology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, North Carolina 27157, USA<br><i>Infect Immun</i> 74:1113-20. 2006</div><div class="excerpt">..immunity, we evaluated the efficacy of recombinant Salmonella flagellin as an adjuvant in an acellular <b>plague vaccine</b>. Mice immunized intranasally or intratracheally with the F1 antigen of Yersinia pestis and flagellin exhibited ..</div><li><a href="/bin/l.pl?link=puid_16959385"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge<div class="ol_sub">Amy Palin<br>Department of Pathology, Yale University School of Medicine, 310 Cedar Street LH 315, New Haven, CT 06510, USA<br><i>Vaccine</i> 25:741-50. 2007</div><div class="excerpt">..This VSV-based vaccine vector system has potential as a <b>plague vaccine</b> protecting against virulent strains lacking the F1 protein.</div><li><a href="/bin/l.pl?link=puid_16985495"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Deadly plague versus mild-mannered TLR4<div class="ol_sub">Roman Dziarski<br><i>Nat Immunol</i> 7:1017-9. 2006</div><li><a href="/bin/l.pl?link=puid_12399192"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6<div class="ol_sub">K F Griffin<br>Dstl Biomedical Sciences, Porton Down, Salisbury, SP4 0JQ, Wiltshire, UK<br><i>Vaccine</i> 20:3650-7. 2002</div><div class="excerpt">..pestis strain GB; however protective efficacy was impaired by co-encapsulating either IFN-gamma or IL-4 with rV...</div><li><a href="/bin/l.pl?link=puid_14522457"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles<div class="ol_sub">Leenu Sabhnani<br>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India<br><i>FEMS Immunol Med Microbiol</i> 38:215-29. 2003</div><div class="excerpt">..Newer methods of antigen delivery coupled with adjuvant offer an alternative approach toward a <b>plague vaccine</b>. In order to develop a new generation vaccine against plague, we chose an immunodominant, outer membrane ..</div><li><a href="/bin/l.pl?link=puid_12126905"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague<div class="ol_sub">E D Williamson<br>Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 OJQ, UK<br><i>Vaccine</i> 20:2933-41. 2002</div><div class="excerpt">..pestis compared with priming only with plasmid DNA encoding the V antigen and boosting with rV. This enhancement may be due to the effect of CpG motifs known to be present in the plasmid DNA construct encoding PA...</div><li><a href="/bin/l.pl?link=puid_12756802"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Vaccination with plasmid DNA expressing the Yersinia pestis capsular protein F1 protects mice against plague<div class="ol_sub">Haim Grosfeld<br>Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, P O Box 19, Ness Ziona, Israel 74100<br><i>Adv Exp Med Biol</i> 529:423-4. 2003</div><li><a href="/bin/l.pl?link=pmcid_PMC143422"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen<div class="ol_sub">Haim Grosfeld<br>Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona 74100, Israel<br><i>Infect Immun</i> 71:374-83. 2003</div><div class="excerpt">..Taken together, these observations indicate that a tailored genetic vaccine based on a bacterial protein can be used to confer protection against plague in mice without resorting to regimens involving the use of purified proteins...</div><li><a href="/bin/l.en together, these observations indicate that a tailored genetic vaccine based on a bacterpl?link=puid_12756800"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Immunological characterisation of sub-units of the Yersinia type III secretion apparatus<div class="ol_sub">James Hill<br>Swedish Defence Research Agency, FOI, NBC Defence, 901 82 Ume√•, Sweden<br><i>Adv Exp Med Biol</i> 529:415-7. 2003</div><li><a href="/bin/l.pl?link=puid_17252929"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Outbreak of duck plague (duck herpesvirus enteritis) in numerous species of captive ducks and geese in temporal conjunction with enforced biosecurity (in-house keeping) due to the threat of avian influenza A virus of the subtype Asia H5N1<div class="ol_sub">E F Kaleta<br>Klinik fur Vogel, Reptilien, Amphibien und Fische, Justus Liebig Universitat Giessen, Frankfurter Strasse 91 93, 35392 Giessen<br><i>Dtsch Tierarztl Wochenschr</i> 114:3-11. 2007</div><div class="excerpt">..The remaining healthy appearing birds were subcutaneously vaccinated with a modified live duck <b>plague vaccine</b> (Intervet, Boxmeer, NL) that stopped losses and resulted in seroconversion in most of the vaccinated birds.</div><li><a href="/bin/l.pl?link=pmcid_PMC1168899"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Immunization of mice with YscF provides protection from Yersinia pestis infections<div class="ol_sub">Jyl S Matson<br>Department of Microbiology and Immunology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202, USA<br><i>BMC Microbiol</i> 5:38. 2005</div><div class="excerpt">..pestis strains and could lead to a high rate of undesired side effects in vaccinated populations. For these reasons, the use of other antigens in a <b>plague vaccine</b> formulation may be advantageous.</div><li><a href="/bin/l.pl?link=puid_12009274"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Determination of the virulence of the pigmentation-deficient and pigmentation-/plasminogen activator-deficient strains of Yersinia pestis in non-human primate and mouse models of pneumonic plague<div class="ol_sub">S Welkos<br>Division of Bacteriology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702 5011, USA<br><i>Vaccine</i> 20:2206-14. 2002</div><div class="excerpt">The current human <b>plague vaccine</b>, a killed Yersinia pestis whole-cell preparation, does not protect against aerosol challenge and is reactogenic and antigenically undefined. Live attenuated Y...</div><li><a href="/bin/l.pl?link=pmcid_PMC2074897"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>A surface-focused biotinylation procedure identifies the Yersinia pestis catalase KatY as a membrane-associated but non-surface-located protein<div class="ol_sub">Tanya Myers-Morales<br>Did_PMC2074897"><img src="/img/pmc.gif" class="epartment of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536 0298, USA<br><i>Appl Environ Microbiol</i> 73:5750-9. 2007</div><div class="excerpt">..be exposed to the surface and might be a candidate for evaluation as a protective antigen for an improved <b>plague vaccine</b>. KatY was obtained only in the total membrane fraction, and stachyose greatly reduced its biotinylation as ..</div><li><a href="/bin/l.pl?link=puid_19366573"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Small protective fragments of the Yersinia pestis V antigen<div class="ol_sub">Claire Vernazza<br>Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire, SP4 0JQ, UK<br><i>Vaccine</i> 27:2775-80. 2009</div><div class="excerpt">..pestis as a bioweapon fuel the need for efficacious vaccines. The most recent <b>plague vaccine</b> is a killed whole cell preparation that is expensive to manufacture and its side effects are common...</div><li><a href="/bin/l.pl?link=puid_20415784"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis<div class="ol_sub">G Gupta<br>Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India<br><i>Scand J Immunol</i> 71:186-98. 2010</div><div class="excerpt">..In present study, microencapsulated B-T constructs after intranasal immunization generated systemic as well as mucosal immune response in all three sites, which offers an alternative approach for <b>plague vaccine</b>.</div><li><a href="/bin/l.pl?link=puid_19789982"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation<div class="ol_sub">M Lucrecia Alvarez<br>Center for Infectious Diseases and Vaccinology, The Biodesign Institute at Arizona State University, 1001 South McAllister Avenue, Tempe, AZ 85287 5401, USA<br><i>Plant Mol Biol</i> 72:75-89. 2010</div><div class="excerpt">..As a part of a project to develop a plant-made <b>plague vaccine</b>, we expressed our model antigen, the Yersinia pestis F1-V antigen fusion protein, with and without a fused ..</div><li><a href="/bin/l.pl?link=pmcid_PMC2857377"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection<div class="ol_sub">Petra C F Oyston<br>Department of Biomedical Sciences, Defence Science and Technology Laboratory, Porton Down, Salisbury, Wiltshire SP4 0JQ, United Kingdom<br><i>Microb Pathog</i> 48:191-5. 2010</div><div class="excerpt">..pestis auxotrophic for guanine and avirulent; such a strain could serve as a live attenuated <b>plague vaccine</b> candidate. A Y...</div><li><a href="/bin/l.pl?link=puid_16209555"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague<div class="ol_sub">Bradford S Powell<br>United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 1201, USA<br><i>Biotechnol Prog</i> 21:1490-510. 2005</div><div class="excerpt">..protection over the former licensed product, establish a foundation from which to create a robust production process, and set forth assays for the development of F1-V as the active pharmaceutical ingredient of the next <b>plague vaccine</b>.</div><li><a href="/bin/l.pl?link=puid_22537022"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>A Yersinia pestis YscN ATPase mutant functions as a live attenuated vaccine against bubonic plague in mice<div class="ol_sub">Joel Bozue<br>Division of Bacteriology, US Army Medical Research Institute of Infectious Diseases, Ft Detrick, MD, USA<br><i>FEMS Microbiol Lett</i> 332:113-21. 2012</div><div class="excerpt">..Antibodies to F1 capsule but not to LcrV were detected in sera from the vaccinated mice. These preliminary results suggest a proof-of-concept for an attenuated, genetically engineered, live vaccine effective against bubonic plague...</div><li><a href="/bin/l.pl?link=pmcid_PMC3582797"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells<div class="ol_sub">Kwang Chul Kwon<br>Department of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Biomolecular Science Building, Orlando, FL 32816 2364, USA<br><i>Adv Drug Deliv Rev</i> 65:782-99. 2013</div><div class="excerpt">....</div><li><a href="/bin/l.pl?link=puid_19635609"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Protection against anthrax and plague by a combined vaccine in mice and rabbits<div class="ol_sub">Jun Ren<br>State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 FengTai Dongdajie Street, Beijing 100071, PR China<br><i>Vaccine</i> 27:7436-41. 2009</div><div class="excerpt">..2x10(5) colony-forming units (CFU) virulent B. anthracis spores. These data show that the protective efficacy was unaffected when the antigens were administered in combination...</div><li><a href="/bin/l.pl?link=puid_23480362"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 iens were administered in combination...</div><li><a href="/bin/l.pl?link=puid_23480362"><immune response in murine model<div class="ol_sub">R Ali<br>Department of Biochemistry, All India Institute of Medical Sciences AIIMS, New Delhi 110029, India<br><i>Scand J Immunol</i> 77:361-71. 2013</div><div class="excerpt">..This study proposes a new perspective for the development of vaccination strategies for Y.¬†pestis that trigger T cell immune response...</div><li><a href="/bin/l.pl?link=puid_19116945"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Biophysical characterization and formulation of F1-V, a recombinant plague antigen<div class="ol_sub">Ajit Joseph M D'souza<br>BD Technologies, 21 Davis Dr, Research Triangle Park, North Carolina 27519, USA<br><i>J Pharm Sci</i> 98:2592-602. 2009</div><div class="excerpt">..5, F1-V appears to populate predominantly in its monomeric state...</div><li><a href="/bin/l.pl?link=pmcid_PMC3625312"><img src="/img/pmc.gif" class="small" alt="pmc"> </a>In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine<div class="ol_sub">Pan Tao<br>Department of Biology, The Catholic University of America, Washington, DC 20064, USA<br><i>Proc Natl Acad Sci U S A</i> 110:5846-51. 2013</div><div class="excerpt">..Mice delivered with a single dose of F1-V <b>plague vaccine</b> containing both gene and protein in the T4 head elicited robust antibody and cellular immune responses.4, USA<br><i>Proc Natl Acad Sci U S A</i> 110:5846-51. 2013</div><div class="excerpt">..Mice delivered with a single dose of F1-V <b>plague vaccine</b>..</div><li><a href="/bin/l.pl?link=puid_23750796"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Live-attenuated Yersinia pestis vaccines<div class="ol_sub">Xiaoyi Wang<br>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, 100071, China<br><i>Expert Rev Vaccines</i> 12:677-86. 2013</div><div class="excerpt">Plague caused by Yersinia pestis is one of the most dangerous infectious diseases. There is no ideal <b>plague vaccine</b> available for human use, but a number of licensed killed whole-cell and live-attenuated vaccines have been available in ..</div><li><a href="/bin/l.pl?link=puid_23908395"><img src="/img/ncbi.gif" class="small" alt="ncbi"> </a>Preclinical safety assessment of a recombinant plague vaccine (rF1V)<div class="ol_sub">Jessica L Price<br>DynPort Vaccine Company LLC, A CSC Company, 64 Thomas Johnson Drive Frederick, MD 21702, USA Email<br><i>Int J Toxicol</i> 32:327-35. 2013</div><div class="excerpt">..The rF1V vaccine produced no apparent systemic toxicity and only transient edema and erythema at the injection site. Together these results indicated a favorable safety profile for rF1V and supported its use in a Phase 1 clinical trial. ..</div></ol></div></div><div class="super_box"><h3 class="super_box_header">Research Grants<span class="bar_note">23</span></h3><div class="super_box_content"><ol><li><a href="/grant/r01/ai/identification/of/identification-of-new-antigens-for-a-plague-vaccine-8474680.html">Identification of New Antigens for a Plague Vaccine</a><div class="ol_sub">Ashok K Chopra; Fiscal Year: 2013</div><div class="excerpt">..Although immunization of humans with <b>plague vaccine</b> will discourage the use of Y. pestis as a bioweapon, currently there is no vaccine against plague...</div><li><a href="/grant/r01/ai/cell-mediated/protection/cell-mediated-protection-against-pneumonic-plague-8424303.html">Cell-mediated protection against pneumonic plague</a><div class="ol_sub">Jr Shiuan Lin; Fiscal Year: 2013</div><div class="excerpt">..Thus, <b>plague vaccine</b> researchers have devoted little attention to cellular immunity...</div><li><a href="/grant/r03/ai/evaluation/of/evaluation-of-ail-as-a-protective-immunogen-for-plague-8232034.html">Evaluation of Ail as a protective immunogen for plague</a><div class="ol_sub">Eric S Krukonis; Fiscal Year: 2012</div><div class="excerpt">..There is currently no licensed <b>plague vaccine</b> in the U.S...</div><li><a href="/grant/u01/ai/multivalent/plague/multivalent-plague--anthrax-vaccines-using-bacteriophage-t4-display-8435493.html">Multivalent Plague, Anthrax Vaccines Using Bacteriophage T4 Display</a><div class="ol_sub">Venigalla B Rao; Fiscal Year: 2013</div><div class="excerpt">..genetic, structural, and aerosol challenge expertise, strategies are designed to develop a novel trivalent T4-<b>plague vaccine</b> comprised of three Yersinia Ags, the capsular Ag, Caf1, the low calcium response V Ag, LcrV, and the Yersinia ..</div><li><a href="/grant/r01/ai/the/role/the-role-of-lps-tlr4-signaling-in-live-vaccine-induced-protective-responses-8441620.html">The role of LPS-TLR4 signaling in live vaccine-induced protective responses</a><div class="ol_sub">Egil Lien; Fiscal Year: 2013</div><div class="excerpt">..Currently there is no available licensed <b>plague vaccine</b>, and exploratory vaccines have variable ability to protect against pneumonic disease, the form expected after ..</div><li><a href="/grant/r01/ai/development/of/development-of-enabling-vector-antigen-expression-technology-for-an-orally-delive-8463454.html">Development of Enabling Vector/Antigen Expression Technology for an Orally-Delive</a><div class="ol_sub">B Kim Lee Sim; Fiscal Year: 2013</div><div class="excerpt">..vaccination schedule (6 doses over 18 months) and has concerns over adverse effects;and 3) the lack of a <b>plague vaccine</b> licensed in the United States...</div><li><a href="/grant/r21/ai/improved/plague/improved-plague-vaccine-by-targeting-dendritic-cell-subsets-7860350.html">Improved plague vaccine by targeting dendritic cell subsets</a><div class="ol_sub">Yoonkyung Do; Fiscal Year: 2010</div><div class="excerpt">..Therefore, developing an effective <b>plague vaccine</b>, the goal of this proposal, is relevant to public health. </div><li><a href="/grant/u01/ai/multi-gene/subunit/multi-gene-subunit-vaccine-platform-against-y--pestis-8129744.html">Multi-gene Subunit Vaccine Platform Against Y. pestis</a><div class="ol_sub">Shan Lu; Fiscal Year: 2011</div><div class="excerpt">..Our proposal was developed based on our recent progress in <b>plague vaccine</b> studies which includes 1...</div><li><a href="/grant/r44/ai/evaluation/and/evaluation-and-production-of-a-multivalent-adenoviral-plague-vaccine-8515916.html">Evaluation and Production of a Multivalent Adenoviral Plague Vaccine</a><div class="ol_sub">ERIC ROTHE; Fiscal Year: 2013</div><div class="excerpt">..The <b>plague vaccine</b> project was selected in response to the growing concern surrounding the organism&apos;s possible use in a ..</div><li><a href="/grant/r21/ai/role/of/role-of-yersinia-pestis-ail-in-yop-delivery-and-plague-8231326.html">Role of Yersinia pestis Ail in Yop delivery and plague</a><div class="ol_sub">Eric S Krukonis; Fiscal Year: 2012</div><div class="excerpt">..pestis surface protein Ail with host cells. This critical interaction is required for plague virulence and characterizing this interaction may lead to development of anti-plague therapeutics and/or an effective <b>plague vaccine</b>. </div><li><a href="/grant/r43/ai/development/production/development--production-and-evaluation-of-a-multivalent-adenoviral-plague-vaccine-7676133.html">Development, Production and Evaluation of a Multivalent Adenoviral Plague Vaccine</a><div class="ol_sub">CHRIS LENTZ; Fiscal Year: 2009</div><div class="excerpt">..and Introgen Therapeutics, Inc. The <b>plague vaccine</b> project was selected in response to the growing concern surrounding the organism&apos;s use in a potential ..</div><li><a href="/grant/r21/ai/alternative/endpoints/alternative-endpoints-for-plague-challenge-models-6953798.html">Alternative endpoints for plague challenge models</a><div class="ol_sub">Richard Frothingham; Fiscal Year: 2005</div><div class="excerpt">Yersinia pestis causes human and animal plague. <b>Plague vaccine</b> research has increasing importance since Y. pestis is a potential bioterrorism agent. Published Y. pestis vaccine studies use mortality as the primary endpoint...</div><li><a href="/grant/r43/ai/mucosal/modified/mucosal-modified-vaccinina-ankara-based-plaque-vaccines-7197322.html">Mucosal modified vaccinina Ankara-based plaque vaccines</a><div class="ol_sub">DAN STINCHCOMB; Fiscal Year: 2007</div><div class="excerpt">..goal is to optimize antigen expression by recombinant MVA and develop a highly safe mucosal MVA-based <b>plague vaccine</b> that protects against aerosol exposure to both Y. pestis and smallpox virus. The specific aims are as follows...</div><li><a href="/grant/uc1/ai/development/of/development-of-protollintm-plague-vaccine-6845743.html">Development of ProtollinTM Plague Vaccine</a><div class="ol_sub">George Lowell; Fiscal Year: 2004</div><div class="excerpt">The aim of this work is to develop a nasal sub-unit <b>Plague vaccine</b> using the recombinant Plague antigen F1V formulated with ProteosomeTM-based ProtollinTM adjuvant to provide protection against the bioterror threat posed by aerosol-..</div><li><a href="/grant/r43/ai/plague/vaccine/plague-vaccine-candidates-by-a-functional-genomic-screen-6555454.html">Plague vaccine candidates by a functional genomic screen</a><div class="ol_sub">Kathryn Sykes; Fiscal Year: 2002</div><div class="excerpt">..abstract_text> ..</div><li><a href="/grant/u01/ai/multi-gene/plague/multi-gene-plague-vaccine-with-expanded-protection-6805660.html">Multi-gene plague vaccine with expanded protection</a><div class="ol_sub">Shan Lu; Fiscal Year: 2004</div><div class="excerpt">The overall objective of this application is to rapidly develop much needed alternative <b>plague vaccine</b> candidate formulations based on our recent discovery that a modified Y...</div><li><a href="/grant/r21/ai/surface/proteins/surface-proteins-in-pneumonic-plague-6901848.html">Surface proteins in pneumonic plague</a><div class="ol_sub">SUSAN STRALEY; Fiscal Year: 2005</div><div class="excerpt">..These studies will provide the technical base for a more detailed screen for new <b>plague vaccine</b> candidates...</div><li><a href="/grant/u01/ai/lcrv/plague/lcrv-plague-vaccine-with-altered-immune-modulatory-properties-7491091.html">LcrV Plague Vaccine with Altered Immune Modulatory Properties</a><div class="ol_sub">Olaf Schneewind; Fiscal Year: 2008</div><div class="excerpt">..the associated suppression of host defense mechanisms may preclude the use of full length LcrV as a human <b>plague vaccine</b>. Herein we show that short deletions within LcrV can reduce its immune modulatory properties...</div><li><a href="/grant/r01/hl/roles/for/roles-for-coagulation-in-immunity-6923667.html">Roles for coagulation in immunity</a><div class="ol_sub">STEPHEN SMILEY; Fiscal Year: 2005</div><div class="excerpt">..Deciphering those mechanisms may lead to improved vaccines and/or treatments for pathologies characterized by fibrin deposition, including autoimmunity, allograft rejection, cancer and septic shock. </ABSTRACT_TEXT> ..</div><li><a href="/grant/r21/ai/priming/cd4/priming-cd4--t-cells-to-protect-against-pneumonic-plague-6710630.html">Priming CD4+ T cells to protect against pneumonic plague</a><div class="ol_sub">STEPHEN SMILEY; Fiscal Year: 2004</div><div class="excerpt">..Our long-term goals are to use that information to develop effective pneuinonic plague vaccines.</ABSTRACT_TEXT> ..</div><li><a href="/grant/r56/ai/cell-mediated/protection/cell-mediated-protection-against-pneumonic-plague-7623267.html">Cell-mediated protection against pneumonic plague</a><div class="ol_sub">STEPHEN SMILEY; Fiscal Year: 2008</div><div class="excerpt">..Thus, <b>plague vaccine</b> researchers have devoted little attention to cellular immunity...</div><li><a href="/grant/p01/ai/respiratory/immunity/respiratory-immunity-against-agents-of-bioterrorism-7447884.html">Respiratory Immunity Against Agents of Bioterrorism</a><div class="ol_sub">STEVEN MIZEL; Fiscal Year: 2008</div><div class="excerpt">....</div><li><a href="/grant/r01/ai/activation/of/activation-of-inflammatory-cells-by-flagellin-7032346.html">Activation of inflammatory cells by flagellin</a><div class="ol_sub">STEVEN MIZEL; Fiscal Year: 2006</div><div class="excerpt">..Furthermore, the proposed studies should also provide insights into the factors that regulate TLR signaling and allow for complex patterns of host cell response. ..</div></ol></div></div></div>
	</div>
  </div>
  <div id="footer_main"><!-- main footer-->
    <div id="footer_hr">&nbsp;</div>
    <div id="copyright">Labome.Org &copy; 2015 All Rights Researved<br />Princeton, New Jersey 08540, USA<br /><div id="date">last updated: January 04, 2015</div> </div>
    <!-- end main footer--></div>
</body>
</html>
      
